FORUM

CMC Management in Regulatory Affairs

From the CMC Manager‘s everyday business life

Dear Reader

In today‘s rapidly evolving pharmaceutical landscape, Chemistry, Manufacturing, and Controls (CMC) regulatory compliance has become more complex and critical than ever. With stringent global regulations, emerging safety concerns like N-nitrosamines, and the imperative for Quality by Design principles, pharmaceutical companies face unprecedented challenges in bringing safe, effective products to market.

This whitepaper outlines the essential priorities that form the cornerstone of successful CMC regulatory strategy – from ensuring global compliance with evolving EU frameworks to implementing robust lifecycle management systems that support innovation while maintaining the highest quality standard.

We wish you many new insights while reading.



This whitepaper is AI developed using NotebookLM and edited by Dr Birgit Wessels, conference manager of the FORUM Institute.

CMC Management in Regulatory Affairs: From the CMC Manager's everyday business life

This comprehensive overview delves into Regulatory Affairs Chemistry, Manufacturing, and Controls (RA CMC), its legal framework, the submission process for medicinal products, and the management of post-approval changes, drawing heavily on International Council on Harmonisation (ICH) guidelines and European Union (EU) legislation.

1) Regulatory Affairs CMC in a Nutshell

CMC stands for Chemistry, Manufacturing, and Controls, encompassing knowledge and compilation of information on the manufacturing process, quality control, release testing, specifications, stability, and manufacturing facilities. RA CMC professionals play a central role in the development, licensing, manufacture, and marketing of pharmaceutical products, assuring consistent levels of effectiveness, safety, and quality for consumers. Their broader responsibilities include developing global strategies, liaising with authorities, preparing and reviewing regulatory submissions (product development), developing manufacturing process strategies to meet regulatory requirements (regulatory compliance), and assessing/predicting emerging trends in policies, regulations, and guidelines (regulatory intelligence). RA CMC interfaces with various departments, including Quality Assurance, R&D, Production, Clinical, and Supply.

Legal Framework

All medicines must be authorized before they can be marketed and made available to patients, as mandated by Directive 2001/83/EC, which is being replaced by revised EU pharmaceutical legislation. This strong regulation was triggered by scandals like thalidomide in the late 1950s. The legal framework ensures public health protection, quality, safety, and efficacy of authorized medicines, requiring a positive benefit-risk balance. Quality criteria are detailed in Annex 1 of Directive 2001/83/EC and associated guidelines, while safety and efficacy are demonstrated through clinical trials and continuous monitoring (Pharmacovigilance).

The EU legal framework includes regulations (directly applicable) and directives (requiring member states to incorporate content into national legislation), alongside guidelines. In the United States, there are laws, regulations, and guidances. EudraLex is the collection of rules and regulations for medicinal products in the EU, consisting of 10 volumes, including Volume 1 for human medicinal products (e.g., Directive 2001/83/EC, Regulations 726/2004 and 536/2014) and Volume 4 for Good Manufacturing Practice (GMP).

A significant reform of the EU pharmaceutical legislation was proposed on April 26, 2023, aiming to enhance supply security and availability, ensure timely and equitable access to safe, effective, and affordable medicines, make medicines more environmentally sustainable, and foster an innovation-friendly environment for R&D and production in Europe, while also addressing antimicrobial resistance. The European Pharmacopoeia (Ph. Eur.) holds legal status in the EU, providing legally binding quality standards for substances, finished products, classes of substances, and dosage forms.

The International Council on Harmonisation (ICH) is a key international body comprising regulatory bodies, industry, and organizations, which develops guidelines for the registration of pharmaceuticals for human use.

Submission Process and Common Technical Document (CTD)

In the EU, several routes for authorizing medicines are available, including the centralized, national, mutual-recognition, and decentralized procedures. Requirements for marketing authorization are detailed in Directive 2001/83/EC and Regulation (EC) No 726/2004.

The CTD is a harmonized format for submitting detailed information on medicines to regulatory authorities for market approval. It is an obligatory format, with an electronic version known as eCTD that facilitates creation, review, lifecycle management, and archiving of submissions. The CTD is structured into five modules:

- **Module 1:** Administrative and prescribing information
- **Module 2:** Overviews and summaries of modules 3 to 5
- **Module 3:** Quality (CMC)
- **Module 4:** Safety (nonclinical studies)
- **Module 5:** Efficacy (clinical studies)

2) Quality Data for Marketing Authorization (Module 3)

Drug Substance (Module 3.2.S)

Essential quality data for the drug substance (API) in module 3 includes starting materials, physicochemical properties, manufacturing process and development, impurities, and stability.

- **Starting Materials and Intermediates:** An „API starting material“ is incorporated as a significant structural fragment into the API, while an „Intermediate“ is produced during API processing that undergoes further molecular change or purification. Non-isolated intermediates are generally not accepted as starting materials in the CMC dossier. Intermediates that contribute essential structural elements or are exclusively produced for APIs must be under GMP conditions. Suppliers of critical starting materials and intermediates must be assessed. API starting materials can be „custom synthetized chemicals“ (requiring a synthesis flow sheet and specification) or „commodities“ (commercially available for non-pharma use as well, requiring essential impurity profile information). The API manufacturer must justify where the synthesis starts from a regulatory perspective. Water used for API synthesis must comply with WHO guidelines for potable water or the EU Drinking Water Directive. All starting materials must be included in a systematic risk assessment regarding the final API, especially for N-nitrosamine formation and DNA reactive (mutagenic) impurities (ICH M7).
- **Physicochemical Properties (3.2.S.3):** Elucidation of structure (3.2.S.3.1) typically involves elemental analysis, NMR, IR, MS, and X-ray crystallography, with all spectra and interpretations included. Other characteristics (3.2.S.3.1) include stereochemistry (racemate vs. specific isomer), polymorphism (different forms, dissolution, bioavailability, manufacturability, patent protection), and Particle Size Distribution (PSD). PSD is critical if it affects dissolution, solubility, bioavailability, manufacturability, stability, content uniformity, or appearance.
- **Manufacturing Process (3.2.S.2):** ICH Q11 describes approaches to developing and understanding the drug substance manufacturing process. The goal is to establish a commercial process capable of consistently producing drug substance of intended quality. This involves identifying Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). Manufacturers and all involved sites (including contract manufacturers and labs) must be listed with unambiguous addresses. The synthesis process must be described in detail with a flow chart, indicating batch size, solvents, and In-Process Controls (IPCs). Final crystallization or milling steps, which determine physical properties, should also be described. Alternative synthesis processes and reprocessing steps must be identified and described in detail, with assessment of resulting impurity profiles. Process validation for non-sterile APIs from chemical synthesis is a GMP topic and not

generally included in the CMC dossier, but is required for biotechnological products and sterilization processes for APIs. A Manufacturing Process Development summary (3.2.S.2.6) should explain development steps, CQAs, and essential process changes. Two approaches exist: „traditional“ (identifying CQAs, developing processes to meet them, defining control strategy) and „enhanced“ (additionally identifying material attributes and functional relationships linking them to CQAs, supporting design space).

- **Impurities (3.2.S.3.2):** Identification and control of impurities are essential. ICH Q3A(R2) classifies impurities into organic (process- and drug-related), inorganic, and residual solvents. Organic impurities can arise from starting materials, by-products, intermediates, degradation products, reagents, ligands, and catalysts. Inorganic impurities include reagents, heavy metals, inorganic salts, and other materials, with elemental impurities additionally covered by ICH Q3D(R2). Other contaminants like different polymorphic forms and enantiomeric impurities are not covered by ICH Q3A and require separate addressing. Impurities introduced in early synthesis stages may be better purged than those introduced later. ICH Q3A(R2) sets thresholds for reporting (>0.05%), identification (0.1%), and qualification (0.15% for <2g daily dose). Qualification involves establishing the biological safety of an impurity, often through toxicological risk assessment or studies. The impurity profile of generic APIs should be close to the originator‘s product.
- **Elemental Impurities and N-Nitrosamines:** ICH Q3D(R2) addresses elemental contamination from various sources (manufacturing, natural contaminants, equipment, packaging). N-nitrosamines were detected in APIs containing tetrazole rings (sartans) in 2018, leading to recalls. Contamination can stem from impurities in solvents (e.g., dimethylformamide with sodium nitrite), raw materials (secondary amines, disinfected water, recycled solvents), and risks in the synthesis process (presence of amines and nitrosating agents, high temperature, acidic medium, cross-contamination). Acceptable Intake (AI) limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) are set by authorities like FDA and EMA.
- **Setting API Specifications (3.2.S.4):** A specification includes a list of tests, references to analytical procedures, and acceptance criteria, proposed by applicants and justified. Specifications confirm quality, not full characterization. Pharmacopoeial methods should be applied where appropriate. Key specification items include description (solid state, color, crystallinity), identification (specific methods like IR, chromatography), assay/potency (stability-indicating method, limits considering impurity levels), organic and inorganic impurities, and residual solvents (Class 1 to be avoided, Class 2 limited by PDE, Class 3 with low toxic potential). Justification of specification refers to development data, pharmacopoeial standards, and stability studies.
- **Reference Standards or Materials (3.2.S.5):** Standards are classified as primary (pharmacopoeial or fully characterized internal substance) or secondary (generated by characterization against primary standards). Purity requirements depend on intended use.
- **Stability Testing (3.2.S.7):** Stability data establish shelf life for drug products and re-test periods for APIs. Minimum data from 3 batches of pilot scale or more are required. Primary packaging should simulate the market container. Stress testing on a single batch (temperature, humidity, pH, photostability per ICH Q1B) helps establish degradation pathways. ICH Q1A(R2) outlines storage conditions (real time: 25°C/60%RH, intermediate: 30°C/65%RH or 75%RH, accelerated: 40°C/75%RH) and cold storage conditions. Extrapolation of re-test periods is possible under certain conditions. A draft ICH Q1 guideline (April 2025) aims to revise and combine existing stability requirements.

Drug Product (Module 3.2.P)

Module 3.2.P contains essential quality data for the drug product, with sections often mirroring those for the drug substance.

- **Description and Composition (3.2.P.1):** Brief description of the dosage form, name, and container/closure system. Composition lists all components (amount, function, quality standards).
- **Pharmaceutical Development (3.2.P.2):** This section, guided by ICH Q8(R2), presents knowledge gained from scientific approaches and quality risk management to develop a high-quality product and manufacturing process. It forms the basis for regulatory flexibility.
  - **Components:** Identification and discussion of physicochemical/biological properties of the drug substance influencing performance/manufacturability. For excipients, discussion on choice, concentration, and characteristics influencing performance/manufacturability.
  - **Drug Product (3.2.P.2.2):** Formulation development involves summarizing development and suitability, identifying critical attributes, and discussing selection/concentration of excipients. Overages (e.g., to compensate for manufacturing losses) must be justified, but overages to compensate for degradation or extend shelf life are discouraged. Physicochemical and biological properties relevant to safety, performance, or manufacturability (e.g., pH, potency, particle size) are discussed.
  - **Manufacturing Process Development (3.2.P.2.3):** Discussion of selection and optimization, focusing on critical aspects and steps, and differences between clinical and commercial processes. Quality by Design (QbD) emphasizes building quality in by design, rather than testing it in. This systematic approach uses predefined objectives, process and product understanding, and process control based on sound science and quality risk management. The „process defines the product," especially for biologics and complex drugs.
  - **Container Closure System (3.2.P.2.4):** Discussion of suitability, function (protection), sorption, and safety (extractables and leachables).
  - **Microbiological Attributes (3.2.P.2.5):** Discussion of antimicrobial preservative systems, critical contamination process steps, and overall control concept (bioburden, endotoxins, media fills, sterile filter validation).
  - **Compatibility (3.2.P.2.6):** Compatibility with application devices, reconstitution/suspension agents, and co-administered drugs.
- **Manufacture (3.2.P.3):** Lists all manufacturers (3.2.P.3.1), batch formula (3.2.P.3.2) including quantitative composition. The manufacturing process (3.2.P.3.3) is described with a flow diagram, narrative, identified process controls, and major equipment. Controls of Critical Steps and Intermediates (3.2.P.3.4) require description, justification, and experimental batch data. Process Validation (3.2.P.3.5) is the documented evidence that a procedure operates effectively and reproducibly, typically involving 3 consecutive batches at production scale. It's a GMP requirement to be performed prior to commercialization.
- **Control of Excipients (3.2.P.4):** Excpients are constituents other than the active substance. Specifications (3.2.P.4.1) differentiate between pharmacopoeial (Ph. Eur., other Pharmacopoeias like USP) and non-pharmacopoeial excipients. Bioburden and endotoxin limits for excipients in sterile products are important. Novel excipients (used for the first time or by a new route) require full details of manufacture, characterization, and controls.
- **Control of Drug Product (3.2.P.5):**
  - **Specifications (3.2.P.5.1):** Define tested parameters, analytical methods, and accepted ranges for both release and shelf-life. Guidance comes from ICH Q6A/Q6B.
  - **Analytical Procedures (3.2.P.5.2):** Detailed descriptions of analytical methods, including sample preparation, reference standards, apparatus, calibration, and calculation.

- **Validation of Analytical Procedures (3.2.P.5.3):** Summaries of validation studies, with reports and chromatograms, covering parameters like specificity, accuracy, precision (repeatability, intermediate precision, reproducibility), detection limit, quantitation limit, linearity, range, and robustness. Revalidation is needed for changes in drug substance synthesis, finished product composition, or analytical procedures.
- **Batch Analyses (3.2.P.5.4):** Batch analysis data (or CoAs) for at least three drug product batches are required, along with data from pre/post-process change batches and non-clinical/clinical batches.
- **Characterization of Impurities (3.2.P.5.5):** Guided by ICH Q3B (drug products), ICH Q3C (residual solvents), ICH Q3D (elemental impurities), ICH M7, and EMA guidance for nitrosamines. Principles are similar to drug substance impurity control.
- **Justification of Specifications (3.2.P.5.6):** Justification focuses on deviations from standard ranges, based on clinical studies, process knowledge, and safety data. Justification for the absence of certain parameters (e.g., impurities not included in specification) is also required.

- **Reference Standards or Materials (3.2.P.6):** Information on standards used for testing the medicinal product, with CoAs.
- **Container Closure System (3.2.P.7):** Required information includes identity of packaging material, specifications, drawings, and method validation for non-compendial methods.
- **Stability (3.2.P.8):** Purpose is to provide evidence of how finished product quality varies over time under environmental factors (temperature, humidity, light) to establish shelf life and storage conditions. Stability studies must test attributes susceptible to change influencing quality, safety, and/or efficacy. Minimum requirements include at least 12 months long-term and 6 months accelerated data from 3 primary batches (2 pilot scale minimum). Matrixing and Bracketing designs allow for reduced testing. In-use stability studies cover the period a multi-dose product can be used after opening, simulating patient use.

3) Pharmaceutical Writing and Quality Overall Summary (QOS)

Effective pharmaceutical writing emphasizes plain language for clarity and understanding, considering audience, purpose, structure, design, expression, and evaluation. The eCTD style guide (ICH M4(R4)) mandates unambiguous, transparent information display, legible font sizes (e.g., Times New Roman, 12-point), page numbering, and definition of acronyms/abbreviations. Consistent wording, spelling, symbol conventions, and well-formatted tables are crucial.

The Quality Overall Summary (QOS) is a condense summary of module 3‘s integral quality information, significantly shorter than module 3 itself. It provides regulators with a quicker understanding of the product‘s benefit-risk profile and overall control strategy from a quality perspective. The QOS follows the same structure as module 3 and should contain no new data or justifications. Updates or addenda to the QOS are mandatory for all quality type II variations. ICH M4Q(R2) is under revision to expand its scope, integrate ICH quality guidelines, and enhance module 2 for submission and assessment efficiency.

Common mistakes in drug substance documentation include insufficient justification of starting materials, incompletely specified impurity profiles, lack of clarity on polymorphic forms or PSD impact, and missing links between API batches and development stages. Manufacturing process descriptions may be insufficiently detailed, and control strategies or CQA justifications may be missing. Stability studies often fail to comply with ICH storage conditions or lack photostability data.

- **Active Substance Master Files (ASMF):** Provide detailed API information to authorities. Options include a full CTD Section 3.2.S, partly referencing an ASMF, or using a Certificate of Suitability (CEP). An ASMF has an applicants part (open), filed by the Marketing Authorization Holder (MAH), and a restricted part (closed), filed by the API manufacturer. The API manufac-

turer provides a Letter of Access. The ASMF is not applicable to biologicals. A worksharing process has been implemented for ASMF assessment in the EU. The MAH holds sole responsibility for the drug product, ensuring access to all relevant API information. Future EU legislation proposes a new ASMF procedure where the API manufacturer would apply to EMA for an ASMF certificate, integrated into the MAA, and EMA would establish a repository of ASMFs.

- **Certificate of Suitability (CEP):** Issued by the EDQM, a CEP certifies that an API can be tested and released based on the respective monograph of the European Pharmacopoeia. Parameters not in Ph. Eur. may be annexed to the CEP. The MAH is responsible for following up on CEP status and dossier updates. The MAH can agree on additional individual requirements (e.g., PSD) with the CEP holder. CEPs do not confirm GMP conformity; this is confirmed by the API manufacturer in their application, with EDQM/EMA conducting onsite audits. CEP 2.0 implements new processes since September 2023, requiring EMA SPOR/OMS ORG_ID and LOC_ID and replacing the Declaration of Access Box with a Letter of Access. EDQM has clarified responsibilities regarding elemental impurities (ICH Q3D) and nitrosamine risk for CEPs.
- **Drug Substance Analysis by Finished Product Manufacturer:** For a single API supplier using ASMF/CEP, the MAH‘s specification should ideally be identical, though redundant tests or outdated methods don‘t need to be adopted. For multiple API sources, a single compiled specification identical for each supplier is preferred, potentially with different acceptance criteria or analytical methods for a single parameter. Selecting a generic API source involves GMP audits, scientific criteria (different salts, polymorphic forms, impurity profiles), and business criteria (sustainability, market price, second source recommendation).

4) Challenges in the Interdisciplinary Field

- **GMP Meets Regulatory Affairs:** Consistent quality of medicinal products is ensured by process/product understanding, control strategy, quality risk management, and a pharmaceutical quality system (ICH Q8, Q9, Q10, Q11). QbD is a systematic development approach emphasizing process and product understanding. Regulatory Affairs is involved in Product Quality Reviews (PQR), contributing regulatory changes and their dates. RA is an interface to GMP, GCP, GLP functions and is involved in GMP processes like Change Control. A formal change management system, guided by ICH Q10, is crucial for post-approval changes, involving quality risk management and expert team evaluations.
- **GMP Documents for Submissions:** Module 1.2 includes the electronic Application Form (eAF) and annexes like Manufacturing and Import Licenses (MIAs), flow-charts, GMP certificates, TSE certificates, and the Qualified Person (QP) declaration confirming GMP compliance of active substance manufacture. The EudraGMDP database provides information on manufacturing/import/wholesale authorizations and GMP/GDP certificates. Other GMP documents include Certificates of Analysis (CoAs), batch certification by the QP (ensuring compliance with GMP and MA), and Process Validation data (though validation is a GMP requirement, a process validation scheme might be submitted if validation is not yet completed).
- **Nonclinical and Clinical Meets CMC:** Nonclinical (module 4) and Clinical (module 5) development aims to identify drug candidates, prove concepts, determine doses, develop safety data, describe physicochemical characteristics, and show comparability after process changes. CMC interfaces with nonclinical (e.g., toxicity assessments for impurities, definition of CQAs for efficacy) and clinical (e.g., dissolution for pharmacokinetics, impurities for safety, batch data linkage).
- **Challenges for Advanced Therapy Medicinal Products (ATMPs):** Due to their novelty, ATMPs (based on genes, tissues, or cells) require more non-clinical studies, robust potency assays (quantitative measure of biological activity), and extensive comparability exercises after process changes to ensure no impact on quality, safety, and clinical efficacy.

5) Management of Post-Approval Changes

The MAH must inform the Regulatory Authorities about any change in manufacturing, control, or printed matter not compliant with the approved design model. Some changes require prior authority approval. Pharmaceutical lifecycle management is based on QbD development (ICH Q8) and continual improvement (ICH Q10). Planned changes must be evaluated prospectively for regulatory impact.

- **Types of Changes:** GMP-relevant changes relate to manufacturing site layout, HVAC, or non-dossier process parameters. CMC-relevant changes include API source, manufacturing process, release specification, analytical methods, shelf-life, or new technologies. Proactive measures to avoid variations include robust formulation, enhanced QbD, establishing a design space (multidimensional combination of input variables and process parameters that assure quality, allowing changes within it without variation application), and describing equipment generically.
- **Legal Framework for Regulatory Variations:** The EU Variation Regulation 1234/2008 (amended by 2024/1701, effective Jan 2025) and the Classification Guideline 2013/C 223/01 describe and classify changes.
- **Classification of Changes:**
  - **Type IA:** Minor, minimal/no impact on quality, safety, or efficacy (e.g., administrative changes, tightening specifications). Implemented immediately, filed within 12 months („Do and Tell“).
  - **Type IB:** Minor, not Type IA or Type II (e.g., minor ASMF changes, >10-fold batch size increase). Submit variation, implement if no unfavorable opinion after 30 days („Tell, Wait and Do“).
  - **Type II:** Major, significant impact on quality, safety, or efficacy (e.g., new therapeutic indication, widening specifications, substantial manufacturing process changes). Implement only after authority approval.
  - **Extension:** Listed in Annex I of the regulation (e.g., change to different salt/ester, new strength, new pharmaceutical form).
  - **Urgent Safety Restrictions:** Interim changes due to new safety information, requiring subsequent variation filing.
- **Variation Process:** Classification is performed by the MAH, but authorities can request reclassification. Timelines vary by type and authorization procedure (National, Decentralized/Mutual-Recognition Procedure (DCP/MRP), Centralized Procedure (CP)).
- **Grouping and Worksharing:**
  - Grouping allows submitting several changes in one application, either for one MA or identical variations for multiple MAs (supergrouping for Type IA). Grouped variations are processed according to the highest classification level.
  - Worksharing involves assessment by one authority for multiple affected countries, for the same Type IB/II variation(s) affecting multiple MAs of the same holder. This aims to save resources.
- **Draft Revision of Variation Guidelines:** A March 2024 amendment to Regulation 1234/2008 (effective Jan 2025) aims to align with new ICH lifecycle management concepts. New tools like super grouping and annual updates for Type IA variations are introduced, and mandatory worksharing in specified cases. The framework for biological APIs/finished products and medical devices has been reviewed.
- **Company Internal Processes:** A change management system (ICH Q10) ensures continual improvement and prevents unintended consequences. Regulatory Affairs identifies linked changes, assesses regulatory impact, decides on submission strategy, and communicates with internal/external partners. Regulatory compliance involves the QP certifying batch release compliance

with the MA dossier.

- **Renewal of Marketing Authorizations:** MAs typically require renewal after 5 years, which often leads to unlimited validity after the first successful renewal.
- **Article 61(3) Procedure:** Applicable to minor changes to the Package Insert (PIL) and label not connected to SmPC changes (not a variation application).
- **ICH Q12 (Lifecycle Management):** Provides a framework for predictable and efficient post-approval CMC changes, promoting continual improvement. Key elements include Established Conditions (ECs), which are product/process parameters with significant impact on quality, required in the CMC dossier, and legally binding. Changes to ECs require variations. Post-Approval Change Management Protocols (PACMPs) prospectively describe studies to support future changes, potentially allowing lower variation categories. The Product Life Cycle Management (PLCM) document is a summary of all discussed elements (control strategy, ECs, PACMPs, commitments) aiming for transparency. However, the EU legal framework currently does not fully support ECs and PLCM as described in ICH Q12, emphasizing that legal framework takes precedence over guidelines.
- **ICH Q14 (Analytical Procedure Development):** Covers the lifecycle of analytical methods for APIs and drug products, including multivariate methods and real-time release testing. It describes minimal and enhanced approaches to method development, analogous to ICH Q8/Q11. The Analytical Target Profile (ATP), an element of the enhanced approach, describes the intended purpose and performance criteria for analytical procedures, linked to the Quality Target Product Profile (QTPP).

Conclusion

Top priorities of a CMC Manager

As a CMC manager, top priorities revolve around ensuring the quality, safety and efficacy of pharmaceutical products throughout their lifecycle while navigating the complex global regulatory environment.

Ensuring Global Regulatory Compliance: Maintain full compliance with all relevant laws, regulations, and guidelines across the world, especially within the EU‘s evolving legal framework (EudraLex, Directives like 2001/83/EC, and Regulations like 726/2004). This involves continuously monitoring and adapting to new legislation, such as the ongoing reform of EU pharmaceutical legislation aiming to enhance supply security and foster innovation.

Implementing Quality by Design Principles: Embed QbD into all development processes, ensuring that product quality is built in by design, rather than merely tested in. This means defining a QTPP, identifying CQAs of both drug substance and drug product, and understanding CPPs to establish a robust control strategy.

Establishing Robust Manufacturing Processes and Controls: A critical focus is on ensuring that manufacturing processes for both drug substance and drug product are well-understood, controlled, and validated to consistently produce products of the intended quality. This includes detailed process descriptions, controls of critical steps, and appropriate process validation. For biologics and complex drugs, the CMC Manager needs to emphasize that „the process defines the product“, making process development and knowledge key.

Comprehensive Impurity Control, especially N-Nitrosamines: Given the significant safety concerns and regulatory scrutiny, a top priority is the systematic identification, assessment, and control of all impurities – organic, inorganic, residual solvents, elemental, and particularly N-nitrosamines. This requires thorough risk assessments covering raw materials, synthesis processes, and even packaging components to mitigate nitrosamine formation.

Effective Lifecycle Management of Post-Approval Changes: Focus on efficiently managing post-approval CMC changes to marketed products, recognizing their classification (Type IA, IB, II, or extension) and associated timelines and documentation. This involves strategically leveraging tools like ECs and PACMPs to streamline future changes and facilitate continual improvement.

Diligent Management of API and Excipient Sources: Ensuring the quality and compliance of all incoming materials is paramount. This includes a robust process for selecting and managing API and excipient suppliers, whether through full CTD sections, ASMFs, or CEPs. The CMC Manager needs to ensure that all critical starting materials and intermediates are produced under appropriate GMP conditions and that supplier assessments are conducted.

Accurate and Clear Regulatory Writing and Submission: Preparing high-quality, unambiguous, and transparent regulatory submissions is vital. This means adhering to CTD structure (especially module 3), eCTD style guides (ICH M4), and plain language principles for clarity and navigability, particularly for the Quality Overall Summary (QOS). The goal is to provide regulators with a quick and comprehensive understanding of the product‘s quality and control strategy.

Comprehensive Stability Programs: Ensure that robust stability studies are conducted for both drug substances and finished products to establish appropriate re-test periods and shelf-lives, and to define recommended storage conditions. This includes stress testing to understand degradation pathways and photostability testing where applicable.

Robust Analytical Method Development and Validation: It‘s crucial that all analytical procedures used for testing raw materials, in-process controls, drug substances, and drug products are developed effectively, fully validated, and fit for their intended purpose. The CMC Manager needs to keep an eye on new guidelines like ICH Q14 that introduce lifecycle management principles for analytical procedures.

Fostering Strong Cross-Functional Collaboration: RA CMC serves as a key interface between various departments, including R&D, Production, Quality Assurance, Clinical, and Non-clinical. The CMC Manager’ priority is to ensure seamless communication and collaboration to gather and integrate all necessary CMC information, manage changes effectively (e.g., through change control systems), and support product development and commercialization.

Other offers

Practical regulatory affairs and vigilance knowledge

Our regulatory courses and conferences provide practical information on the fundamentals and trends in marketing authorisation, regulatory maintenance and post-marketing surveillance. More information.

e-Learning – Click and learn

The FORUM Institut offers a flexible form of training with quality e-learning courses.
You decide for yourself when and where to learn. Test free now.

In-house seminars – Tailored solutions

All our seminars are also perfect for in-house training.
Request a personalised quotation now.

FORUM · Institut für Management GmbH · Vangerowstraße 18 · 69115 Heidelberg · Germany
Phone: +49 6221 500-500 · Fax: +49 6221 500-555 · www.forum-institut.com